Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 7/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.48 |
| ▸ | HRH2 | P25021 | 5/20 | 0.48 |
| ▸ | HRH1 | P35367 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1659697 | 0.94 | MAOB (0.50) | MMP2ALDH1A1HPGDMMP3HRH3 | |
| SCHEMBL17856189 | 0.88 | MMP2 (0.58) | MMP2ALDH1A1HPGDMMP3HRH3 | |
| SCHEMBL197283 | 0.85 | FYN (0.45) | MMP2MMP3MMP9MAOB | |
| SCHEMBL18937750 | 0.83 | ALDH1A1 (0.59) | MMP2ALDH1A1HPGDMMP3HRH3 | |
| SCHEMBL11121921 | 0.83 | MMP2 (0.58) | MMP2ALDH1A1MMP3HRH3HRH2 | |
| SCHEMBL11784760 | 0.81 | MAOB (0.57) | MMP2ALDH1A1MMP3HRH3HRH2 | |
| SCHEMBL12550024 | 0.80 | HDAC1 (0.58) | MMP2ALDH1A1HPGDMMP3HRH3 | |
| SCHEMBL19130590 | 0.80 | HDAC1 (0.58) | MMP2ALDH1A1HPGDMMP3HRH3 | |
| SCHEMBL15581343 | 0.80 | HDAC1 (0.58) | MMP2ALDH1A1HPGDMMP3HRH3 | |
| SCHEMBL12726667 | 0.80 | NQO1 (0.58) | MMP2ALDH1A1HPGDMMP3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7416682-B2 | Photochromic liquid crystals | CHI MEI OPTOELECTRONICS CORPORATION (TW) | 2008-08-26 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | MMP2 4839/4885ALDH1A1 3512/4885HPGD 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.